CD163 and non-small cell lung carcinoma: In total, 271 NSCLC cases were evaluable for all eight CTAs, with complete annotation for all 11 immune markers (CD3, CD4, CD8, CD20, CD45RO, CD138, CD163, FOXP3, NKp46, programmed death 1 [PD‐1], and PD‐L1), mutation status, and overall survival.